Hemera Biosciences Inc.

With proof of concept for its NAV platform from two gene therapy products partners have brought to the market, two products slated for regulatory submission in the next two years, and a new manufactur

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck & Co. Seeks NASH Momentum From Al

Things are looking up for ocular gene therapy, and the timing couldn’t be better. The demand for novel or improved vision therapies is clear: No approved pharmaceutical treatments exist to reverse or

Hemera Biosciences Inc. PO Box 170808 Boston, MA 02117 Phone: (857) 272 3833 Web Site: www.hemerabiosciences.com Contact: Rajendra Kumar-Singh, PhD, Co-founder Industry Segment: Gene therapy